{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-030320","form_type":"8-K","ticker":"APTN","cik":"0001938571","company_name":"ADAPTIN BIO, INC.","filed_at":"2025-04-09T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.519390+00:00","generated_at":"2026-05-23T18:36:45.857663+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Adaptin Bio completes reverse merger and $7.7M private placement for glioblastoma trial","bullets":["Reverse merger of Unite Acquisition 1 Corp. subsidiary with Adaptin; Adaptin survives and will trade on OTC Markets.","Private placement of 1,400,342 shares with Series A (1-yr, $4.40) and Series B (5-yr, $6.60) warrants.","$1.5M promissory notes converted at $3.30/share; total gross proceeds ~$7.7M.","Proceeds to fund Phase 1 trial of APTN-101 for glioblastoma after FDA IND clearance.","Post-closing: Lucius Partners and former Adaptin holders each hold ~3.25M shares."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-030320","json":"https://secwatch.observer/filing/0001213900-25-030320.json","markdown":"https://secwatch.observer/filing/0001213900-25-030320.md","text":"https://secwatch.observer/filing/0001213900-25-030320.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1938571/000121390025030320/0001213900-25-030320-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1938571/000121390025030320/ea0237436-8k_adaptin.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T18:36:45.857663+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}